Merck: CMV inhibitor Premin launched in China
ADC评论
August 8, 2022
On August 5, Merck announced that its novel non-nucleoside cytomegalovirus (CMV) inhibitor, Premin® (Litemovir Tablets), was officially launched in China for patients undergoing allogeneic hematopoietic
